PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35190631-6	2022	Moreover, the CDK inhibitor dinaciclib and O-GlcNAcylation inhibitor OSMI1 reduced the number of CSCs derived from these cells.	dinaciclib	28-38	cyclin-dependent kinase 1	Mus musculus	14-17	
31300540-6	2019	We validated that inhibitors of these druggable target genes, including the CDK1/CDK2 inhibitor dinaciclib, had antiproliferative and cytotoxic effects selectively on mouse prostate cells with knockdown of Chd1 and Map3k7.	dinaciclib	96-106	cyclin-dependent kinase 1	Mus musculus	76-80	
21768779-3	2011	Dinaciclib (SCH727965) is a novel small molecule multi-CDK inhibitor with low nanomolar potency against CDK1, CDK2, CDK5 and CDK9 that has shown favorable toxicity and efficacy in preliminary mouse experiments, and has been well tolerated in Phase I clinical trials.	dinaciclib	0-10	cyclin-dependent kinase 1	Mus musculus	104-108	
21768779-3	2011	Dinaciclib (SCH727965) is a novel small molecule multi-CDK inhibitor with low nanomolar potency against CDK1, CDK2, CDK5 and CDK9 that has shown favorable toxicity and efficacy in preliminary mouse experiments, and has been well tolerated in Phase I clinical trials.	dinaciclib	12-21	cyclin-dependent kinase 1	Mus musculus	104-108